LYN and acute myeloid leukemia: In addition, PTK2 overexpression, concomitantly with PTK2B or LYN underexpression, identifies a patient subgroup with very poor outcome among IR-AML patients bearing non-favorable FLT3/NPM1 combinations with highly heterogeneous outcome.